Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.

Bixia TangZhihong ChiYingbo ChenXiufeng LiuDi WuJing ChenXin SongWeifeng WangLihou DongHaifeng SongHai WuHui FengSheng YaoShuikui QinXiaoshi ZhangJun Guo

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

This is the largest prospective anti-PD-1 clinical study in advanced melanoma with predominantly acral and mucosal subtypes. Toripalimab demonstrated a manageable safety profile and durable clinical response in Chinese patients with metastatic melanoma refractory to standard therapy.See related commentary by Shoushtari et al., p. 4171.

Keyphrases

skin cancer
double blind
randomized controlled trial
basal cell carcinoma
african american
cell therapy